Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, Jetzt den vollständigen Artikel lesen

https://www.investing.com/news/company-news/edwards-lifesciences-executive-sells-over-87k-in-company-stock-93CH-3580395

SINGAPORE , Aug. 19, 2024 /PRNewswire/ -- Genesis MedTech has sold JC Medical, Inc. to Edwards Lifesciences, including the intellectual property and commercial rights of its J-Valve® System, a transcatheter aortic valve replacement for the treatment of severe aortic regurgitation. The transaction includes an upfront payment plus potential sales-based contingent milestones. Genesis MedTech has maintained the exclusive right to develop, manufacture and commercialize the J-Valve® Systemin in Greater China . In July 2023 , Genesis MedTech successfully completed patient enrollment for clinical study of J-Valve transfemoral system for the treatment of aortic regurgitation (referred to as J-Valve® TF) in China , and recently concluded the one-year patient follow-up. In August 2023 , JC Medical''s J-Valve® TF was granted the "Breakthrough Device Designation" by the U.S. Food and Drug Administration (FDA). JC Medical completed enrollment in its early feasibility study (EFS) of J-Valve® TF in the United States in February 2024 .

David Rolfe''s Strategic Moves in Edwards Lifesciences Corp Highlight Q2 2024 Investments

While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks. According to a McKinsey & Company report, over the next five years, the industry may see the fastest growth in the realms of cardiovascular health, digital healthcare and robotics. Overall, the MedTech ecosystem reached a valuation of $503.2 billion last year , per Future Market Insights. By 2033, the sector could be worth nearly $776.5 billion. If so, the expansion would imply a compound annual growth rate (CAGR) of 4.4%. Fundamentally, chronic conditions such as diabetes, cardiovascular disease and obesity are on the rise globally. Therefore, MedTech stocks will likely benefit from burgeoning relevance. While it may be tempting to view the medical innovation space cynically, we should also note that chronic disease imposes a collective economic impact. Therefore, these MedTech stocks offer a win-win for everyone.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. ` The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30 , according to Benzinga Pro . Here''s the latest list of major oversold players in this sector, having an RSI near or below 30. Edwards Lifesciences Corp (NYSE: EW ) On July 24, Edwards Lifesciences reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix. The company''s stock fell … Full story available on Benzinga.com

Mad Money'' host Jim Cramer weighs in on stock including: Borr Drilling, Blackstone, Dexcom, Edwards Lifesciences, Lowe''s, Joby, and Marvell.

Have you assessed how the international operations of Edwards Lifesciences (NYSE: EW ) performed in the quarter ended June 2024? For this medical device maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. In today''s increasingly interconnected global economy, a company''s ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company''s reliance on overseas markets has become increasingly crucial, as it offers insights into the company''s sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential. Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

Edwards Lifesciences stock dropped by over 31% after cutting TAVR guidance. Read why I remain confident in EW stock''s long-term growth potential.

The CNN Money Fear and Greed index showed a further decline in the overall market sentiment, with the index remaining in the “Fear” zone on Thursday. U.S. stocks closed mixed on Thursday, with the S&P 500 and the Nasdaq Composite moving lower after recording sharp losses in the prior session. Shares of leading technology companies, including, Nvidia (NASDAQ: NVDA ), while Meta Platforms (NASDAQ: META ), Microsoft (NASDAQ: MSFT ) and Alphabet (NASDAQ: GOOG ) (NASDAQ: GOOGL ) settled lower on Thursday. Ford Motor Company (NYSE: F ) shares tumbled over 18% on Thursday after the company missed analyst EPS estimates for the 2024 fiscal year second quarter. Shares of Edwards Lifesciences Corporation (NYSE: EW ) dipped 31% after the company … Full story available on Benzinga.com